Dr Reddy’s Laboratories announced today that it launched Valganciclovir tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE{+®} (Valganciclovir) tablets, in the US market on December 15.
The anti-viral drug has got approval from the United States Food & Drug Administration (USFDA).
The Valcyte tablets brand had US sales of approximately $440 million MAT for the most recent 12 months ending in October 2014, according to IMS Health.
Dr Reddy’s Valganciclovir tablets, USP in 450 mg is available in bottle counts of 60, the Hyderabad-based company said in a press release.